Zimbabwe has turned down a major American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for confidential biological samples.
This move was revealed following a internal memorandum from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman later clarified that the US was seeking biological samples for scientific study and commercial purposes while was unwilling to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued talks to find a deal suitable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This development follows a comparable case in Kenya, where a high court suspended a similar deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
Based on reports, 16 nations in Africa have to date signed similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no equivalent assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research with no certainty that the end products would be available to our people if a future health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining structures previously established through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This mechanism is designed to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We encourage further discussions with our American counterparts on how subsequent collaboration could be arranged in a way that respects the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but suggested that negotiations must proceed given that a large portion of the country's HIV programmes relied on international support.
"If technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
This impasse underscores the ongoing debate between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.